Table 1.

Clinical and biological patient characteristics




COALL/DCOG cohort

St Jude cohort
ALL subtype, no. patients   
B-other   48   27  
BCR-ABL   5   8  
E2A*  9   12  
Hyperdiploid  44   15  
MLL*  4   5  
TEL-AML1   44   17  
T-lineage   36   9  
Follow-up time, y   
Median   4.8   7.1  
Interquartile range   3.8-5.9   4.9-9.0  
Age, y   
Median   6.0   6.2  
Interquartile range   3.5-10.2   3.3-11.8  
WBC, no./nL   
Median   34.4   36.9  
Interquartile range   10.7-89.1   8.4-93.3  
Clinical response, no. patients   
CCR   143  69  
Relapse
 
45
 
15
 



COALL/DCOG cohort

St Jude cohort
ALL subtype, no. patients   
B-other   48   27  
BCR-ABL   5   8  
E2A*  9   12  
Hyperdiploid  44   15  
MLL*  4   5  
TEL-AML1   44   17  
T-lineage   36   9  
Follow-up time, y   
Median   4.8   7.1  
Interquartile range   3.8-5.9   4.9-9.0  
Age, y   
Median   6.0   6.2  
Interquartile range   3.5-10.2   3.3-11.8  
WBC, no./nL   
Median   34.4   36.9  
Interquartile range   10.7-89.1   8.4-93.3  
Clinical response, no. patients   
CCR   143  69  
Relapse
 
45
 
15
 

This study included 190 samples derived from children with acute lymphoblastic leukemia at diagnosis. CCR indicates continuous complete remission.

*

COALL: MLL and E2A rearranged; St Jude: MLL-AF4 and E2A-PBX1.

Cytogenetic analysis revealed more than 50 chromosomes.

Two patients had a competing event; a secondary malignancy and myelodysplastic syndrome (MDS).

Close Modal

or Create an Account

Close Modal
Close Modal